| 14.56 Data as of May 17 |  +0.13 / +0.90%Today’s Change | 12.50 Today|||52-Week Range 16.99 | -9.23% Year-to-Date |
| Previous close | 14.43 |
| Today’s open | 14.48 |
| Day’s range | 14.26 - 14.65 |
| Volume | 206,842 |
| Average volume (3 months) | 239,565 |
| Market cap | $525.9M |
| Dividend yield | -- |
| Earnings growth (last year) | +1.56% |
| Earnings growth (this year) | +13.85% |
| Earnings growth (next 5 years) | +10.00% |
| Revenue growth (last year) | +3.11% |
| P/E ratio | 23.5 |
| Price/Sales | 2.05 |
| Price/Book | 1.18 |
| Today’s change | Today’s % change | |
|---|---|---|
| ASTXAstex Pharmaceutical... | +0.17 | +3.14% |
| MACKMerrimack Pharmaceut... | +0.04 | +0.73% |
| SNTASynta Pharmaceutical... | +0.01 | +0.13% |
| ECYTEndocyte Inc | +0.12 | +0.84% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | $0.21 |
| Annual revenue (last year) | $281.9M |
| Annual profit (last year) | $23.5M |
| Net profit margin | 8.35% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Daniel J. Abdun-Nabi |
Chief Financial Officer & EVP-Corporate Services Robert G. Kramer, Sr., MBA |
Corporate headquarters Rockville, Maryland |
.
